Phase I safety data on an antisense oligonucleotide for treatinggenital warts were presented last week at the SixthInternational Conference for Antiviral Research in Venice,Italy.

The compound, ISIS 2105, is an antisense construct to humanpapilloma virus, the cause of genital warts, being developed byIsis Pharmaceuticals Inc. (NASDAQ:ISIP) of Carlsbad, Calif. Itwas the first injectable antisense drug to gain investigationalnew drug approval from the FDA.

In the Phase I trials, ISIS 2105 was given to volunteers as anintradermal injection, with no clinically significant side effects.

"The results from this Phase I study provided the groundworkfor the on-going Phase II studies in the U.S.," commented DanielKisner, chief operating officer of Isis. Those Phase II trialsbegan in November 1992. -- Jennifer Van Brunt

(c) 1997 American Health Consultants. All rights reserved.

No Comments